1. An antibody or antigen binding fragment thereof with binding specificity for ICAM-1, or a variant, hybrid or derivative of said antibody, or an antigen binding fragment or hybrid of its specified variant or derivative, with binding specificity for ICAM-1, for use in treating a disorder associated with multiple myeloma, the treatment comprising the step of administering to the patient in need of treatment an effective amount of an antibody, antigen binding fragment, variant, hybrid or derivative thereof for the treatment of disorders a associated with multiple myeloma. 2. The use of an antibody or antigen binding fragment thereof with binding specificity for ICAM-1, or a variant, hybrid or derivative of said antibody, or an antigen binding fragment or hybrid of its specified variant or derivative, with binding specificity for ICAM-1, for the manufacture of a medicament for the treatment of a disorder associated with multiple myeloma, the treatment comprising the step of administering to the patient in need of treatment an effective amount of an antibody, its antigen binding fragment, variant, hybrid yes or derivative thereof for the treatment of a disorder associated with multiple mielomoy.3. A method for treating a disorder associated with multiple myeloma in a patient, the method comprising the step of administering to the patient in need of treatment an effective amount of an antibody or antigen binding fragment thereof with binding specificity to ICAM-1, or a variant, hybrid or derivative of the indicated antibody, or antigen binding fragment or a hybrid of its specified variant or derivative, with special1. Антитело или его связывающий антиген фрагмент со специфичностью связывания с ICAM-1,или вариант, гибрид или производное указанного антитела, или связывающий антиген фрагмент или гибрид его указанного варианта или производного, со специфичностью связывания с ICAM-1,для применения в лечении расстройства, связанного с множественной миеломой, причем лечение вк
